Samsung Biologics signs up to supply Enzolytics with COVID-19, HIV drugsnews2021-10-07T14:23:07+00:00October 7th, 2021|Fierce Pharma|
Flu shots and Moderna’s COVID-19 booster can be given during the same doctor’s visit, Sanofi study findsnews2021-10-07T13:42:47+00:00October 7th, 2021|Fierce Pharma|
Amid ‘reshoring’ efforts, central Virginia looks to bolster drug supply strengthnews2021-10-07T13:21:27+00:00October 7th, 2021|Fierce Pharma|
Moderna to pour $500M into Africa to meet future mRNA vaccine manufacturing demandnews2021-10-07T12:33:53+00:00October 7th, 2021|Fierce Pharma|
Merck’s molnupiravir will be a blockbuster drug during pandemic. What about endemic COVID-19?news2021-10-07T12:14:18+00:00October 7th, 2021|Fierce Pharma|
Pilot launch complete: GlaxoSmithKline’s malaria shot scores WHO backing for wider rollout in Africanews2021-10-06T18:14:50+00:00October 6th, 2021|Fierce Pharma|
Biogen, mRNA players on Merck’s M&A radar as CEO still hungry for deals after $11.5B Acceleron buy: FTnews2021-10-06T15:31:08+00:00October 6th, 2021|Fierce Pharma|
Buyers clamor for Merck’s COVID-19 antiviral molnupiravir, but pricing is already controversialnews2021-10-06T14:23:08+00:00October 6th, 2021|Fierce Pharma|
With D.C. drug pricing talks up in the air, the ‘endgame’ could still ‘have a bite,’ analyst saysnews2021-10-06T13:58:17+00:00October 6th, 2021|Fierce Pharma|
NICE backs Novartis’ Adakveo via special channel despite ‘high uncertainty’ about cost, long-term efficacynews2021-10-06T13:23:01+00:00October 6th, 2021|Fierce Pharma|
